These have been shown to have nephroprotective effects in some studies.[76,80] However their effects on eGFR were uncertain as shown in a recent Cochrane review.[80] SGLT2 inhibitors were found to have a nephroprotective effect as shown in DECLARE-TIMI 58 and EMPA-REG OUTCOME trials, but in the Cochrane review, it did not show any effect on AKI risk.[80–82]. Here, SLC5A2 is linked to acute kidney injury.